[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656148":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":34,"studyPopulation":35,"armGroups":36,"interventions":30,"overallOfficials":40,"centralContacts":45,"locations":30,"responsibleParty":51,"collaborators":30,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":30,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":30,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":30,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":81,"whyStopped":30,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":30},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":30},[9],{"measure":10,"description":11,"timeFrame":12},"Change in left ventricular ejection fraction","Change in left ventricular ejection fraction (LVEF) percentage measured by transthoracic echocardiography from baseline to 3 months.","From baseline to 3 months",[14,17,20,24,27],{"measure":15,"description":16,"timeFrame":12},"Change in KCCQ-12 score","Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) total score from baseline to 3 months. The KCCQ-12 score ranges from 0 to 100; higher scores indicate better health status and quality of life.",{"measure":18,"description":19,"timeFrame":12},"Change in eGFR","Change in estimated glomerular filtration rate (eGFR, mL\u002Fmin\u002F1.73 m²) calculated by CKD-EPI equation from baseline to 3 months.",{"measure":21,"description":22,"timeFrame":23},"Hospitalization for worsening heart failure","Proportion of patients requiring hospitalization for worsening heart failure.","Up to 3 months",{"measure":25,"description":26,"timeFrame":23},"Cardiovascular mortality","Proportion of patients who die from cardiovascular causes.",{"measure":28,"description":29,"timeFrame":23},"Worsening renal function","Proportion of patients with worsening renal function defined as an increase in serum creatinine ≥0.3 mg\u002FdL or ≥25% from baseline.",null,{"allocation":30,"interventionModel":30,"interventionModelDescription":30,"primaryPurpose":30,"observationalModel":32,"timePerspective":33,"maskingInfo":30},"COHORT","PROSPECTIVE","Heart failure with reduced ejection fraction (HFrEF) remains a major cause of morbidity and mortality. Guideline-directed medical therapy (GDMT) with the four foundational drug classes has improved outcomes in clinical trials, but real-world short-term data from low- and middle-income settings are limited.\n\nThis observational study will include adult patients with chronic HFrEF (LVEF ≤40%) who are stable on or planned for initiation of guideline-directed medical therapy. Patients will be followed for 3 months with assessment of left ventricular ejection fraction, quality of life (KCCQ-12), renal function, and clinical events.","Adult patients with chronic heart failure with reduced ejection fraction (LVEF ≤40%) attending the Cardiovascular Department of Assiut University Hospitals.",[37],{"label":38,"type":30,"description":39,"interventionNames":30},"Single cohort: Patients with HFrEF on GDMT","Adult patients with chronic heart failure with reduced ejection fraction who are receiving or planned to receive guideline-directed medical therapy and will be followed for 3 months.",[41],{"name":42,"affiliation":43,"role":44},"Ayman k Mohammed, prof","Cardiovascular medicine Department, Assiut University Hospitals","STUDY_CHAIR",[46],{"name":47,"role":48,"phone":49,"phoneExt":30,"email":50},"omar N Sayed, Resident","CONTACT","+20 10 64544293","Omar.18323493@med.aun.edu.eg",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Omar Nasr Sayed Ahmed","Resident Physician","100656148","short-term-outcomes-of-hfref-patients-on-guideline-directed-medical-therapy-100656148",false,"NCT07821801","Short-Term Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy","Short-Term Outcomes of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) in View of Current Guideline-Directed Medical Therapy","Inclusion Criteria:\n\n* \\- Age 18 years or older\n* Diagnosis of chronic HFrEF (LVEF ≤40%) documented by echocardiography\n* Stable on or planned initiation of guideline-directed medical therapy\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* \\- Acute decompensated heart failure requiring intravenous inotropes at enrollment\n* End-stage renal disease on dialysis\n* eGFR \\\u003C20 mL\u002Fmin\u002F1.73 m² at baseline\n* Severe primary valvular disease requiring intervention\n* Life expectancy less than 3 months due to non-cardiac illness","ALL","18 Years",{"count":65,"type":66},250,"ESTIMATED","3 Months","OBSERVATIONAL","This prospective cohort study aims to evaluate short-term (3-month) clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical therapy at Assiut University Hospitals.",[71,72],"Heart Failure","Heart Failure, Systolic",[74,75,76,77,78,79,80],"therapy","LVEF","Guideline-directed medical","KCCQ-12","HFrEF","GDMT","Assiut","NOT_YET_RECRUITING","2026-09-15",{"date":84,"type":85},"2026-09-17","ACTUAL",{"date":87,"type":66},"2026-09-10",{"date":89,"type":66},"2028-03-20",{"name":5,"class":6}]